Dr. Runaas on Impactful Targeted Therapies in FLT3-Positive AML

Lyndsey Runaas, MD
Published: Friday, May 31, 2019



Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).

FLT3-mutant AML is not an uncommon subtype of AML as it is present in one-third of patients. Historically, it has been associated with a pretty poor prognosis, but over the past few years, a variety of FLT3 inhibitors have come to market with more in the pipeline.

The next question is how to best sequence these agents, says Runaas. A better understanding on whether it matters which FLT3 inhibitor is given to patients at which time is needed. To try and further that understanding, physicians have the data from the phase III RATIFY trial, which looked at the oral FLT3 inhibitor midostaurin (Rydapt) in combination with standard 7+3 chemotherapy for patients with newly diagnosed AML. Although there wasn't a difference in response rates, the overall survival difference between patients who were treated with midostaurin versus those who received placebo is significant, says Runaas, especially considering that the survival data were censored for the patients who went on to receive transplant.

In the relapsed/refractory setting of FLT3-positive AML, gilteritinib (Xospata) is FDA approved based on data from the phase III ADMIRIAL trial. Quizartinib is another agent being studied in the phase III QuANTUM-R trial. Both agents may be suitable options in this setting, although there is still more to learn, concludes Runaas.
SELECTED
LANGUAGE


Lyndsey Runaas, MD, an assistant professor at the Medical College of Wisconsin, discusses impactful targeted therapies for patients with FLT3-mutant acute myeloid leukemia (AML).

FLT3-mutant AML is not an uncommon subtype of AML as it is present in one-third of patients. Historically, it has been associated with a pretty poor prognosis, but over the past few years, a variety of FLT3 inhibitors have come to market with more in the pipeline.

The next question is how to best sequence these agents, says Runaas. A better understanding on whether it matters which FLT3 inhibitor is given to patients at which time is needed. To try and further that understanding, physicians have the data from the phase III RATIFY trial, which looked at the oral FLT3 inhibitor midostaurin (Rydapt) in combination with standard 7+3 chemotherapy for patients with newly diagnosed AML. Although there wasn't a difference in response rates, the overall survival difference between patients who were treated with midostaurin versus those who received placebo is significant, says Runaas, especially considering that the survival data were censored for the patients who went on to receive transplant.

In the relapsed/refractory setting of FLT3-positive AML, gilteritinib (Xospata) is FDA approved based on data from the phase III ADMIRIAL trial. Quizartinib is another agent being studied in the phase III QuANTUM-R trial. Both agents may be suitable options in this setting, although there is still more to learn, concludes Runaas.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x